基于多参数MRI的影像组学特征鉴别临床显著性与非显著性前列腺癌:机器学习方法的交叉验证
纳入280例病理证实的前列腺癌患者,从多参数MRI提取819个影像组学特征,经SMOTE平衡、mRMR选择与LASSO建模,构建鉴别临床显著性与非显著性前列腺癌的影像组学特征。训练队列AUC 0.872、敏感度0.883、特异度0.753,测试队列AUC 0.823、敏感度0.841、特异度0.727。
要点
- 基于多参数MRI的影像组学特征或可无创鉴别临床显著性与非显著性前列腺癌。
- 训练队列AUC 0.872(95% CI 0.823-0.921),敏感度0.883,特异度0.753。
- 测试队列AUC 0.823(95% CI 0.669-0.976),敏感度0.841,特异度0.727。
核心结论
- 基于多参数MRI的影像组学特征有潜力无创鉴别临床显著性与非显著性前列腺癌。
研究设计与样本
- 纳入280例病理证实的前列腺癌患者,随机分为训练队列与测试队列,从多参数MRI提取819个影像组学特征,采用SMOTE平衡训练队列少数组,以mRMR选择与LASSO算法筛选特征并构建影像组学特征,以ROC曲线分析评估分类性能。
诊断标准与关键数值
- 影像组学特征鉴别临床显著性与非显著性前列腺癌:训练队列AUC 0.872(95% CI 0.823-0.921),敏感度0.883,特异度0.753。
- 影像组学特征鉴别临床显著性与非显著性前列腺癌:测试队列AUC 0.823(95% CI 0.669-0.976),敏感度0.841,特异度0.727。
- 共选择9个特征用于构建影像组学特征。
- 训练队列与测试队列中临床显著性与非显著性前列腺癌组的影像组学特征差异均有统计学意义(两者p < 0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the performance of a multi-parametric MRI (mp-MRI)-based radiomics signature for discriminating between clinically significant prostate cancer (csPCa) and insignificant PCa (ciPCa).
MATERIALS AND METHODS: Two hundred and eighty patients with pathology-proven PCa were enrolled and were randomly divided into training and test cohorts. Eight hundred and nineteen radiomics features were extracted from mp-MRI for each patient. The minority group in the training cohort was balanced via the synthetic minority over-sampling technique (SMOTE) method. We used minimum-redundancy maximum-relevance (mRMR) selection and the LASSO algorithm for feature selection and radiomics signature building. The classification performance of the radiomics signature for csPCa and ciPCa was evaluated by receiver operating characteristic curve analysis in the training and test cohorts.
RESULTS: Nine features were selected for the radiomics signature building. Significant differences in the radiomics signature existed between the csPCa and ciPCa groups in both the training and test cohorts (p < 0.01 for both). The AUC, sensitivity and specificity of the radiomics signature were 0.872 (95% CI: 0.823-0.921), 0.883, and 0.753, respectively, in the training cohort, and 0.823 (95% CI: 0.669-0.976), 0.841, and 0.727, respectively, in the test cohort.
CONCLUSION: Mp-MRI-based radiomics signature have the potential to noninvasively discriminate between csPCa and ciPCa.
引用
- Min X, Li M, Dong D, et al. Multi-parametric MRI-based radiomics signature for discriminating between clinically significant and insignificant prostate cancer: Cross-validation of a machine learning method. Eur J Radiol. 2019. PMID: 31084754. doi:10.1016/j.ejrad.2019.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。